Compare

FOXO4-DRI vs Larazotide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

FOXO4-DRI

722 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 56% · Mixed 34% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
-151
Energy
-31
Mood
-16
Focus
8
Sleep quality
11

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
-55
Dizziness
-132
Fatigue
-51
Nausea
4
Water retention
11

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
6
0.2–0.4 mg
15
0.4–0.6 mg
23
0.6–1 mg
16
1–2 mg
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing46stacking24side effects22foxo4-dri30

How repeat users are trending

Among repeat reporters, 66% said they felt similar to their last entry, 30% more positive, and 16% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 159 repeat reporters

Larazotide

1343 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-14
Mood
-82
Focus
-135
Sleep quality
-142
Lean mass
-143

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-98
Fatigue
-2
Nausea
10
Water retention
-146
Appetite loss
-143

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
5
0.2–0.4 mg
15
0.4–0.6 mg
19
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
9
5+ mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects13larazotide26

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 295 repeat reporters

Sources (6)

Published sources linked on the FOXO4-DRI and Larazotide wiki pages.

  1. PubMed

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)

    Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017

    Source
    Wiki study page →
  2. PubMed

    Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

    Born E, Lipskaia L, Breau M, et al. Circulation. 2023

    Source
    Wiki study page →
  3. PubMed

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

    Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017

    Source
    Wiki study page →
  4. PubMed

    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet

    Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015

    Source
    Wiki study page →
  5. PubMed

    Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration

    Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026

    Source
    Wiki study page →
  6. PubMed

    The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate

    Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016

    Source
    Wiki study page →